Mechanisms of Cancer Drug Resistance and Sensitivity (U54) (RFA CA 17 009)
- The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Mechanisms of Cancer Drug Resistance and Sensitivity (U54)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394, 93.395.
- This funding opportunity was created on Dec 08, 2016.
- Applicants must submit their applications by Mar 03, 2017.
- Each selected applicant is eligible to receive up to $750,000.00 in funding.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
Browse more opportunities from the same category: Education, Health
Next opportunity: 6-year Steelhead Telemetry Study Analysis and Reporting
Previous opportunity: Evaluation of Clinical Interventions, Surveillance, and Ecological Factors that Influence the Burden of Human Monkeypox in the Democratic Republic of the Congo (DRC)
Grant Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 17 009) also looked into and applied for these:
|Funding Number||Funding Title|
|RFA CA 17 015||Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)|
|RFA CA 17 016||Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)|
|RFA CA 17 002||Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)|
|RFA CA 17 001||Canine Immunotherapy Trials and Correlative Studies (U01)|
|PA 17 138||Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)|
|RFA NS 17 022||Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24)|
|RFA DA 18 003||NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3)|
|RFA OD 17 004||Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U01)|
|RFA OD 17 005||Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U24)|
|RFA CA 17 023||Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33)|
|RFA NR 17 001||Limited Competition: Palliative Care Research Cooperative (PCRC) (U2C)|
|RFA CA 17 024||SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44)|
|RFA CA 17 027||Pediatric Early Phase Clinical Trials Network (UM1)|
|RFA CA 17 031||Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)|
|RFA CA 17 025||Consortium on Translational Research in Early Detection of Liver Cancer (Clinical and Research Centers (U01)|
|RFA CA 17 028||Coordinating Center for the Consortium of Translational Research in Early Detection of Liver Cancer (U24)|
|RFA CA 17 032||Minority-Patient Derived Xenograft (PDX) Development and Trial Center (PDTC) Network (U54)|
|RFA CA 17 042||Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1)|
|RFA CA 17 043||Coordinating Center for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (U24)|
|RFA CA 17 044||Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)|
Grant Application Guides and Resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 17 009", eligibility, application service, and/or application tips? Submit an inquiry below: